Review




Structured Review

PeproTech γ-secretase inhibitor dapt
γ Secretase Inhibitor Dapt, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ-secretase inhibitor dapt/product/PeproTech
Average 90 stars, based on 1 article reviews
γ-secretase inhibitor dapt - by Bioz Stars, 2026-02
90/100 stars

Images



Similar Products

95
MedChemExpress γ secretase inhibitor dapt
γ Secretase Inhibitor Dapt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ secretase inhibitor dapt/product/MedChemExpress
Average 95 stars, based on 1 article reviews
γ secretase inhibitor dapt - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

90
PeproTech γ-secretase inhibitor dapt
γ Secretase Inhibitor Dapt, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ-secretase inhibitor dapt/product/PeproTech
Average 90 stars, based on 1 article reviews
γ-secretase inhibitor dapt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Millipore γ-secretase inhibitor dapt
( A ) KEGG pathway analysis showing pathways positively correlated with SNAI1 expression in metastatic RCC samples ( n = 26). MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine 3′,5′-monophosphate; cGMP, guanosine 3′,5′-monophosphate; PKG, cGMP-dependent protein kinase. ( B ) Relative mRNA expression of SNAI1 in 769-P cells treated with indicated inhibitors for 48 hours. ( C ) Relative mRNA expression of SNAI1 in 769-P cells incubated with or without 25 μM <t>DAPT.</t> DAPT-treated cells were exposed to media with or without BCAA for 16 hours ( n = 3). ( D ) Immunoblot analysis of SNAIL1 expression in 769-P cells treated with specific inhibitors, followed by exposure to media with or without BCAA for 16 hours. ( E and F ) Western blot analysis of indicated proteins in RXF-393 cells (E) and 786-O cells (F) treated with increasing concentrations of BCAA for 16 hours. ( G ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7 . ( H ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7, treated with increasing concentrations of BCAA for 16 hours. In (B) and (C), data are presented as means ± SEM and are representative of at least two independent experiments. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used for (B) and (C). ** P < 0.01 and *** P < 0.001.
γ Secretase Inhibitor Dapt, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ-secretase inhibitor dapt/product/Millipore
Average 90 stars, based on 1 article reviews
γ-secretase inhibitor dapt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Tocris γ-secretase inhibitor dapt
( A ) KEGG pathway analysis showing pathways positively correlated with SNAI1 expression in metastatic RCC samples ( n = 26). MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine 3′,5′-monophosphate; cGMP, guanosine 3′,5′-monophosphate; PKG, cGMP-dependent protein kinase. ( B ) Relative mRNA expression of SNAI1 in 769-P cells treated with indicated inhibitors for 48 hours. ( C ) Relative mRNA expression of SNAI1 in 769-P cells incubated with or without 25 μM <t>DAPT.</t> DAPT-treated cells were exposed to media with or without BCAA for 16 hours ( n = 3). ( D ) Immunoblot analysis of SNAIL1 expression in 769-P cells treated with specific inhibitors, followed by exposure to media with or without BCAA for 16 hours. ( E and F ) Western blot analysis of indicated proteins in RXF-393 cells (E) and 786-O cells (F) treated with increasing concentrations of BCAA for 16 hours. ( G ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7 . ( H ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7, treated with increasing concentrations of BCAA for 16 hours. In (B) and (C), data are presented as means ± SEM and are representative of at least two independent experiments. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used for (B) and (C). ** P < 0.01 and *** P < 0.001.
γ Secretase Inhibitor Dapt, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ-secretase inhibitor dapt/product/Tocris
Average 90 stars, based on 1 article reviews
γ-secretase inhibitor dapt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc γ secretase inhibitor dapt
( A ) KEGG pathway analysis showing pathways positively correlated with SNAI1 expression in metastatic RCC samples ( n = 26). MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine 3′,5′-monophosphate; cGMP, guanosine 3′,5′-monophosphate; PKG, cGMP-dependent protein kinase. ( B ) Relative mRNA expression of SNAI1 in 769-P cells treated with indicated inhibitors for 48 hours. ( C ) Relative mRNA expression of SNAI1 in 769-P cells incubated with or without 25 μM <t>DAPT.</t> DAPT-treated cells were exposed to media with or without BCAA for 16 hours ( n = 3). ( D ) Immunoblot analysis of SNAIL1 expression in 769-P cells treated with specific inhibitors, followed by exposure to media with or without BCAA for 16 hours. ( E and F ) Western blot analysis of indicated proteins in RXF-393 cells (E) and 786-O cells (F) treated with increasing concentrations of BCAA for 16 hours. ( G ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7 . ( H ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7, treated with increasing concentrations of BCAA for 16 hours. In (B) and (C), data are presented as means ± SEM and are representative of at least two independent experiments. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used for (B) and (C). ** P < 0.01 and *** P < 0.001.
γ Secretase Inhibitor Dapt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/γ secretase inhibitor dapt/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
γ secretase inhibitor dapt - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


( A ) KEGG pathway analysis showing pathways positively correlated with SNAI1 expression in metastatic RCC samples ( n = 26). MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine 3′,5′-monophosphate; cGMP, guanosine 3′,5′-monophosphate; PKG, cGMP-dependent protein kinase. ( B ) Relative mRNA expression of SNAI1 in 769-P cells treated with indicated inhibitors for 48 hours. ( C ) Relative mRNA expression of SNAI1 in 769-P cells incubated with or without 25 μM DAPT. DAPT-treated cells were exposed to media with or without BCAA for 16 hours ( n = 3). ( D ) Immunoblot analysis of SNAIL1 expression in 769-P cells treated with specific inhibitors, followed by exposure to media with or without BCAA for 16 hours. ( E and F ) Western blot analysis of indicated proteins in RXF-393 cells (E) and 786-O cells (F) treated with increasing concentrations of BCAA for 16 hours. ( G ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7 . ( H ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7, treated with increasing concentrations of BCAA for 16 hours. In (B) and (C), data are presented as means ± SEM and are representative of at least two independent experiments. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used for (B) and (C). ** P < 0.01 and *** P < 0.001.

Journal: Science Advances

Article Title: HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism

doi: 10.1126/sciadv.adt3552

Figure Lengend Snippet: ( A ) KEGG pathway analysis showing pathways positively correlated with SNAI1 expression in metastatic RCC samples ( n = 26). MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine 3′,5′-monophosphate; cGMP, guanosine 3′,5′-monophosphate; PKG, cGMP-dependent protein kinase. ( B ) Relative mRNA expression of SNAI1 in 769-P cells treated with indicated inhibitors for 48 hours. ( C ) Relative mRNA expression of SNAI1 in 769-P cells incubated with or without 25 μM DAPT. DAPT-treated cells were exposed to media with or without BCAA for 16 hours ( n = 3). ( D ) Immunoblot analysis of SNAIL1 expression in 769-P cells treated with specific inhibitors, followed by exposure to media with or without BCAA for 16 hours. ( E and F ) Western blot analysis of indicated proteins in RXF-393 cells (E) and 786-O cells (F) treated with increasing concentrations of BCAA for 16 hours. ( G ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7 . ( H ) Western blot analysis of indicated proteins in 786-O cells expressing shNC or two independent shRNA targeting HDAC7, treated with increasing concentrations of BCAA for 16 hours. In (B) and (C), data are presented as means ± SEM and are representative of at least two independent experiments. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was used for (B) and (C). ** P < 0.01 and *** P < 0.001.

Article Snippet: The γ-secretase inhibitor DAPT was obtained from MilliporeSigma.

Techniques: Expressing, Incubation, Western Blot, shRNA